Benjamin Graham fit · Defensive deep-value investing
Is Nektar Therapeutics (NKTR) a Benjamin Graham Stock?
Meets only 3/7 Graham criteria — likely overpriced or unstable.
20/100
FNot a fit
3/7 criteria passed
Benjamin Graham's Criteria, Applied to NKTR
P/E ≤ 15
key—
P/B ≤ 1.5
key0.0x
Current ratio ≥ 2
4.2x
Debt / Equity ≤ 1
0.0x
5y profitable
keyNo
Earnings yield ≥ 7%
-23.5%
Revenue growing
-49.9%
How NKTR Scores on Other Strategies
Live Financial Snapshot
Market cap
$1.3B
P/E (TTM)
-
ROIC (TTM)
-17.17%
Gross margin
99.38%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is NKTR's Benjamin Graham fit score?
NKTR scores 20/100 on our Benjamin Graham fit engine — grade F. Meets only 3/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own NKTR?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends NKTR.
How often is this score updated?
NKTR's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends NKTR.